Oxybutynin Chloride
Product Images NDC 69189-6605

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 69189-6605). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxybutynin Xl 5 mg Tablet Label (6918966051)

This is a description of a medication called Oxybutynin XL, manufactured by Mylan, in a 5mg tablet form. The medication comes with an expiration date of 11/10/2016 and a MFG Lot number of 3065924. Additionally, it has an NDC number of 6918966051. The hospital has also assigned their own lot number, which is APF15K11-F. There appears to be some random letters/numbers that cannot be interpreted as readable. The medication was likely received by the hospital AVEFUA McKENNAN in St Falls, SO.*

FDA Label Image

Figure 1: Mean R-oxybutynin Plasma Concentrations Following A Single Dose Of Oxybutynin Chloride Extended-release Tablets 10 mg And Oxybutynin 5 mg Administered Every 8 Hours (n = 23 For Each Treatment). (Fig1)

Mean plasma concentration of R-oxybutynin is being measured. There are references to oxybutynin 5 mg and ER 10 mg. No further context or details are available.*

FDA Label Image

Figure 2: Mean Steady State (± Sd) R-oxybutynin Plasma Concentrations Following Administration Of 5 To 20 mg Oxybutynin Chloride Extended-release Tablets Once Daily In Children Aged 5 To 15. Plot Represents All Available Data Normalized To An Equivalent Of Oxybutynin Chloride Extended-release Tablets 5 mg Once Daily. (Fig2)

FDA Label Image

Number Of Urge Incontinence Episodes Per Week (Fig3)

This appears to be a description of the results from three studies comparing the effectiveness of oxybutynin chloride ER (extended release) to placebo or regular oxybutynin in treating an unknown condition. The studies measured changes from baseline and confidence intervals for the differences between the two groups. The results suggest that oxybutynin chloride ER had a statistically significant effect when compared to the placebo, and a comparable efficacy when compared to regular oxybutynin. There is not enough information to determine the specific condition being studied.*

FDA Label Image

Oxybutynin Chloride Structural Formula (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.